Drug Trial Radar · NCT06977724
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 26, 2025
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement and Rheumatoid arthritis (RA) is a long-lasting autoimmune disease that causes the body's immune system to attack itself. RA targets the body's joints, causing inflammation (swelling, pain, and redness). ABBV-319 exhibits potential B cell depletion in SLE, SjD and RA which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE, SjD and RA. ABBV-319 is an investigational drug being developed for the treatment of SLE , SjD and RA. Participants are placed in 1 of 8 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE, SjD or RA. Around 48 adult participants with SLE, SjD or RA will be enrolled at approximately up to 17 sites worldwide. Participants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Dry Eye Syndrome
- Systemic Lupus Erythematosus
Interventions
ABBV-319Drug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 400 days
- Change from Baseline in B Cells in Blood and TissueTime frame: Up to approximately 400 days
- Maximum Plasma Concentration (Cmax) of ABBV-319Time frame: Up to approximately 400 days
- Time to Cmax (Tmax) of ABBV-319Time frame: Up to approximately 400 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-319Time frame: Up to approximately 400 days
- Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-319Time frame: Up to approximately 400 days
- Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-319Time frame: Up to approximately 400 days
- Percentage of Participants with Detection of Neutralizing Antibodies (nAbs) for ABBV-319Time frame: Up to approximately 400 days
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Life Clinical Trials - Colonial Drive - Margate /ID# 276050
Margate, Florida · Recruiting
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836
Tampa, Florida · Recruiting
Advanced Quality Medical Research /ID# 278462
Orland Park, Illinois · Recruiting
Private Practice - Dr. Ramesh C. Gupta /ID# 275826
Memphis, Tennessee · Recruiting
Integrative Rheumatology of South Texas - Harlingen /ID# 276458
Harlingen, Texas · Recruiting
Les Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre /ID# 272692
Strasbourg, Alsace, France · Recruiting
CHU de Montpellier - Hopital Saint Eloi /ID# 279892
Montpellier, Herault, France · Recruiting
Universitair Medisch Centrum Utrecht /ID# 273398
Utrecht, Netherlands · Recruiting
Amsterdam University Medical Center /ID# 274286
Amsterdam, North Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.